Local Control of Inoperable Metastatic Sarcoma Achieved With SBRT
SBRT of all known metastatic sites was associated with improved PFS and OS among children and young adult patients with inoperable sarcoma.
Sarcoma
Nivolumab Plus Ipilimumab Demonstrated Activity in Angiosarcoma
Nivolumab plus ipilimumab demonstrated antitumor activity among patients with either primary or secondary angiosarcoma, according to phase 2 data.
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Radiomic, Clinical Features Predicted Sarcoma Response to Radiation
Radioresistant sarcoma may require treatment intensification.
Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Radiation for Abdominal, Pelvic Cancers Ups Secondary Sarcoma Risk
Compared with patients who undergo surgery alone for abdominal or pelvic cancers, those who receive radiation and chemotherapy are at elevated risk for secondary sarcomas.
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Pembrolizumab May Improve Outcomes in Some Rare Sarcomas
Treatment of some types of rare sarcomas with pembrolizumab resulted in durable clinical benefit for some patients. Partial response rates were highest in alveolar soft-part sarcoma.
The Twitter Effect on How Oncologists Conduct and Share Research
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
-
Loading...
-
Loading...
Next post in General Oncology
